表紙:喘息およびCOPD治療薬市場:2023年~2033年
市場調査レポート
商品コード
1181117

喘息およびCOPD治療薬市場:2023年~2033年

Asthma & COPD Therapies Market Report 2023-2033

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 248 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=193.91円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

喘息およびCOPD治療薬市場:2023年~2033年
出版日: 2023年01月03日
発行: Visiongain Reports Ltd.
ページ情報: 英文 248 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の喘息およびCOPD治療薬の市場規模は、2033年までに7.31%のCAGRで拡大すると予測されています。新興国市場への進出は今後重要な意味を持つでしょう。特に、米国や欧州の市場は飽和状態にあり、特許切れや後発医薬品との競合、低医療費などにより、成長の鈍化や衰退が見られるため、新興国市場への進出は重要です。

当レポートでは、世界の喘息およびCOPD治療薬市場について調査し、市場の概要とともに、製品別、投与経路別、販売地点別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 喘息およびCOPD治療薬市場のイントロダクション

第4章 市場概要

  • 主な調査結果
  • 市場力学
  • 市場抑制要因
  • 市場機会
    • 遠隔医療
  • ポーターのファイブフォース
  • SWOT分析
  • COVID-19の影響分析

第5章 喘息およびCOPD治療薬市場分析、製品別

  • 主な調査結果
  • 製品セグメント:市場魅力指数
  • 喘息およびCOPD治療薬の市場規模の推定と予測、製品別
  • 抗炎症薬
  • 気管支拡張薬の単剤療法
  • 配合剤

第6章 喘息およびCOPD治療薬市場分析、投与経路別

  • 主な調査結果
  • 喘息およびCOPD治療薬の市場規模の推定と予測、投与経路別
  • 経口
  • 吸入
  • その他

第7章 喘息およびCOPD治療薬市場分析、販売時点別

  • 主な調査結果
  • POSセグメント:市場魅力指数
  • 喘息およびCOPD治療薬の市場規模の推定と予測、販売時点別
  • 小売薬局
  • 病院薬局
  • その他

第8章 喘息およびCOPD治療薬市場分析、地域別

  • 主な調査結果
  • 地域の市場規模の推定と予測

第9章 北米の喘息およびCOPD治療薬市場分析

第10章 欧州の喘息およびCOPD治療薬市場分析

第11章 アジア太平洋の喘息およびCOPD治療薬市場分析

第12章 ラテンアメリカの喘息およびCOPD治療薬市場分析

第13章 中東・アフリカの喘息およびCOPD治療薬市場分析

第14章 企業プロファイル

  • AstraZeneca
  • GSK plc
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Mundipharma
  • Cipla Inc.
  • Pulmatrix
  • TFF Pharmaceuticals, Inc.
  • Respiratorius AB
  • Chiesi Farmaceutici S.p.A.
  • Grifols S.A.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Transpire Bio
  • Verona Pharma plc

第15章 結論と提言

図表

List of Tables

  • Table 1 Asthma & COPD Therapies Market Snapshot, 2023 & 2033 (US$ billion, CAGR %)
  • Table 2 Key Factors Affecting the Bargaining Power of Buyer
  • Table 3 Key Factors Affecting the Bargaining Power of Suppliers
  • Table 4 Key Factors Affecting the Threat of Substitutes
  • Table 5 Key Factors Affecting the Threat of New Entrants
  • Table 6 Key Factors Affecting the Industry Rivalry
  • Table 7 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 8 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 9 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 10 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 11 Asthma & COPD Therapies Market Forecast by Product, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 12 Anti-inflammatory Drugs Segment Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 13 Bronchodilators Monotherapy Segment Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 14 Combination Drugs Segment Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 15 Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 16 Oral Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 17 inhaled Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 18 Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 19 Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 20 Hospital Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 21 Others Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 22 Asthma & COPD Therapies Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 23 North America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 24 North America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 25 North America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 26 U.S. Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 27 U.S. Asthma Prevalence, 2020
  • Table 28 Canada Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 29 Europe Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 30 Europe Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 31 Europe Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 32 Germany Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 33 UK Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 34 France Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 35 Italy Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 36 Spain Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 37 Rest of Europe Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 38 Asia Pacific Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 39 Asia Pacific Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 40 Asia Pacific Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 41 Japan Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 42 China Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 43 India Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 44 Australia Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 45 South Korea Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 46 Rest of Asia Pacific Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 47 Latin America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 48 Latin America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 49 Latin America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 50 Brazil Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 51 Mexico Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 52 Rest of Latin America Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 53 MEA Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 54 MEA Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 55 MEA Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 56 GCC Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 57 South Africa Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 58 Rest of MEA Arabia Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
  • Table 59 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 60 AstraZeneca: Key Marketed Products
  • Table 61 AstraZeneca: Product Benchmarking
  • Table 62 AstraZeneca: Strategic Outlook
  • Table 63 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 64 GSK plc: Product Benchmarking
  • Table 65 GSK plc: Strategic Outlook
  • Table 66 Boehringer Ingelheim: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 67 Boehringer Ingelheim: Product Benchmarking
  • Table 68 Boehringer Ingelheim: Strategic Outlook
  • Table 69 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 71 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 72 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 Viatris Inc.: Product Benchmarking
  • Table 74 Viatris Inc.: Strategic Outlook
  • Table 75 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 77 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 78 Novartis AG: Product Benchmarking
  • Table 79 Novartis AG: Strategic Outlook
  • Table 80 Mundipharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 Mundipharma: Product Benchmarking
  • Table 82 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Cipla Inc.: Product Benchmarking
  • Table 84 Cipla Inc.: Strategic Outlook
  • Table 85 Pulmatrix: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Pulmatrix: Product Benchmarking
  • Table 87 Pulmatrix: Strategic Outlook
  • Table 88 TFF Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 TFF Pharmaceuticals, Inc.: Product Benchmarking
  • Table 90 TFF Pharmaceuticals, Inc.: Strategic Outlook
  • Table 91 Respiratorius AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Respiratorius AB: Product Benchmarking
  • Table 93 Chiesi Farmaceutici S.p.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Chiesi Farmaceutici S.p.A.: Product Benchmarking
  • Table 95 Grifols S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Grifols S.A.: Product Benchmarking
  • Table 97 Grifols S.A.: Strategic Outlook
  • Table 98 Sanofi SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Sanofi SA: Product Benchmarking
  • Table 100 Sanofi SA: Strategic Outlook
  • Table 101 Sunovion Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Sunovion Pharmaceuticals Inc.: Product Benchmarking
  • Table 103 Transpire Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Transpire Bio: Product Benchmarking
  • Table 105 Verona Pharma plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Verona Pharma plc: Product Benchmarking
  • Table 107 Verona Pharma plc: Strategic Outlook

List of Figures

  • Figure 1 Asthma & COPD Therapies Market Segmentation
  • Figure 2 Asthma & COPD Therapies Market by Product: Market Attractiveness Index
  • Figure 3 Asthma & COPD Therapies Market by Route of Administration: Market Attractiveness Index
  • Figure 4 Asthma & COPD Therapies Market by Point of Sale: Market Attractiveness Index
  • Figure 5 Asthma & COPD Therapies Market Attractiveness Index by Region
  • Figure 6 Asthma & COPD Therapies Market: Market Dynamics
  • Figure 7 Porter's Five Forces
  • Figure 8 SWOT Analysis
  • Figure 9 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): "V" Shaped Recovery
  • Figure 10 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): "U" Shaped Recovery
  • Figure 11 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): "W" Shaped Recovery
  • Figure 12 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ Mn, AGR %): "L" Shaped Recovery
  • Figure 13 Asthma & COPD Therapies Market Attractiveness Index by Product
  • Figure 14 Asthma & COPD Therapies Market Forecast by Product, 2023-2033 (US$ billion)
  • Figure 15 Asthma & COPD Therapies Market Share Forecast by Product, 2023, 2028, 2033 (%)
  • Figure 16 Asthma & COPD Therapies Market Attractiveness Index by Product
  • Figure 17 Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
  • Figure 18 Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
  • Figure 19 Oral Market Forecast by Region, 2023-2033 (US$ billion)
  • Figure 20 Oral Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 21 Inhaled Market Forecast by Region, 2023-2033 (US$ billion)
  • Figure 22 Inhaled Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 23 Others Market Forecast by Region, 2023-2033 (US$ billion)
  • Figure 24 Others Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 25 Asthma & COPD Therapies Market Attractiveness Index by Point of Sale
  • Figure 26 Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
  • Figure 27 Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023, 2028, 2033 (%)
  • Figure 28 Retail Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
  • Figure 29 Retail Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 30 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
  • Figure 31 Hospital Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 32 Others Market Forecast by Region, 2023-2033 (US$ billion)
  • Figure 33 Others Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 34 Asthma & COPD Therapies Market Forecast by Region 2023-2033 (Revenue, CAGR%)
  • Figure 35 Asthma & COPD Therapies Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 36 Asthma & COPD Therapies Market by Region, 2023-2033 (US$ bn)
  • Figure 37 North America Asthma & COPD Therapies Market Attractiveness Index
  • Figure 38 North America Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
  • Figure 39 North America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
  • Figure 40 North America Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 41 North America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
  • Figure 42 North America Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 43 North America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
  • Figure 44 North America Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
  • Figure 45 U.S. Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 46 Canada Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 47 Europe Asthma & COPD Therapies Market Attractiveness Index
  • Figure 48 Europe Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
  • Figure 49 Europe Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
  • Figure 50 Europe Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 51 Europe Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
  • Figure 52 Europe Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 53 Europe Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
  • Figure 54 Europe Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
  • Figure 55 Germany Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 56 UK Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 57 France Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 58 Italy Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 59 Spain Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 60 Rest of Europe Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 61 Asia Pacific Asthma & COPD Therapies Market Attractiveness Index
  • Figure 62 Asia Pacific Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
  • Figure 63 Asia Pacific Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
  • Figure 64 Asia Pacific Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 65 Asia Pacific Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
  • Figure 66 Asia Pacific Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 67 Asia Pacific Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
  • Figure 68 Asia Pacific Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
  • Figure 69 Japan Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 70 China Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 71 India Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 72 Australia Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 73 South Korea Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 74 Rest of Asia Pacific Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 75 Latin America Asthma & COPD Therapies Market Attractiveness Index
  • Figure 76 Latin America Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
  • Figure 77 Latin America Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
  • Figure 78 Latin America Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 79 Latin America Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
  • Figure 80 Latin America Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 81 Latin America Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
  • Figure 82 Latin America Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
  • Figure 83 Brazil Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 84 Mexico Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 85 Rest of Latin America Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 86 MEA Asthma & COPD Therapies Market Attractiveness Index
  • Figure 87 MEA Asthma & COPD Therapies Market by Region, 2023, 2028 & 2033 (US$ billion)
  • Figure 88 MEA Asthma & COPD Therapies Market Forecast by Country, 2023-2033 (US$ billion)
  • Figure 89 MEA Asthma & COPD Therapies Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 90 MEA Asthma & COPD Therapies Market Forecast by Route of Administration, 2023-2033 (US$ billion)
  • Figure 91 MEA Asthma & COPD Therapies Market Share Forecast by Route of Administration, 2023 & 2033 (%)
  • Figure 92 MEA Asthma & COPD Therapies Market Forecast by Point of Sale, 2023-2033 (US$ billion)
  • Figure 93 MEA Asthma & COPD Therapies Market Share Forecast by Point of Sale, 2023 & 2033 (%)
  • Figure 94 GCC Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 95 South Africa Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 96 Rest of MEA Asthma & COPD Therapies Market Forecast, 2023-2033 (US$ billion, AGR %)
  • Figure 97 AstraZeneca: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 98 AstraZeneca: Regional Market Shares (%), 2021
  • Figure 99 AstraZeneca: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 100 AstraZeneca: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 101 GSK plc: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 102 GSK plc: Regional Market Shares (%), 2021
  • Figure 103 GSK plc: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 104 GSK plc: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 105 Boehringer Ingelheim: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 106 Boehringer Ingelheim: Regional Market Shares (%), 2021
  • Figure 107 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 108 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2021
  • Figure 109 Teva Pharmaceutical Industries Ltd.: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 110 Teva Pharmaceutical Industries Ltd.: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 111 Viatris Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 112 Viatris Inc.: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 113 Viatris Inc.: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 114 F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 115 F. Hoffmann-La Roche Ltd.: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 116 F. Hoffmann-La Roche Ltd.: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 117 Novartis AG: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 118 Novartis AG: Regional Market Shares (%), 2021
  • Figure 119 Novartis AG: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 120 Novartis AG: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 121 Cipla Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 122 Cipla Inc.: Regional Market Shares (%), 2021
  • Figure 123 Grifols S.A.: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 124 Grifols S.A.: Regional Market Shares (%), 2021
  • Figure 125 Grifols S.A.: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 126 Grifols S.A.: R&D, 2015-2021 (US$ million, AGR%)
  • Figure 127 Sanofi SA: Net Revenue, 2015-2021 (US$ million, AGR%)
  • Figure 128 Sanofi SA: Regional Market Shares (%), 2021
  • Figure 129 Sanofi SA: Gross Profit, 2015-2021 (US$ million, AGR%)
  • Figure 130 Sanofi SA: R&D, 2015-2021 (US$ million, AGR%)
目次
Product Code: PHA1223

The global Asthma & COPD Therapies market is projected to grow at a CAGR of 7.31% by 2033.

“The Asthma & COPD Therapies Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Expansion into Emerging Markets to Offer Lucrative Growth Opportunities

For the overall asthma and COPD market, expansion into the emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth or decline due to patent expiry, generic competition and low healthcare budgets. The economic troubles currently being experienced in a number of emerging markets are likely to lift over the next ten years, returning those nations to continued expansion of their healthcare systems and satisfaction of unmet treatment needs. Inhaled drugs will continue to be less affected by patent expiries, as long as the inhaler patents are intact. Advances in inhaler design will continue to be of vital importance to the market.

Nevertheless, the asthma and COPD market have a potential for a number of blockbuster drugs with increasingly segmented sub-groups of patients. The market also benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases, revenues are expected to increase in the years to come. New combination drugs will drive growth. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups. Future success will on long-term planning, to maximise the revenues for existing drugs (life cycle management), to successfully expand into emerging markets and to identify and address unmet needs in the patient population depend on novel and effective therapies.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the asthma & COPD therapies market evolving?
  • What is driving and restraining the asthma & COPD therapies market?
  • How will each asthma & COPD therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each asthma & COPD therapies submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading asthma & COPD therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the asthma & COPD therapies projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of

asthma & COPD therapies projects taking place now and over the next 10 years?

  • Is there a greater need for product commercialisation to further scale the asthma & COPD therapies market?
  • Where is the asthma & COPD therapies market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the asthma & COPD therapies market today, and over the next 10 years:

  • Our 248-page report provides 107 tables and 130 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the asthma & COPD therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product

  • Anti-inflammatory Drugs
  • Bronchodilators Monotherapy
  • Combination Drugs

Route of Administration

  • Oral
  • Inhaled
  • Others

Point of Sale

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Asthma & COPD Therapies Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols S.A.
  • GSK plc
  • Mundipharma
  • Novartis AG
  • Pulmatrix
  • Respiratorius AB
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TFF Pharmaceuticals, Inc.
  • Transpire Bio
  • Verona Pharma plc
  • Viatris Inc.

Overall world revenue for Asthma & COPD Therapies Market, 2023 to 2033 in terms of value the market will surpass US$47 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Asthma & COPD Therapies Market, 2023 to 2033 report help you?

In summary, our 240+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Asthma & COPD Therapies Market, 2023 to 2033 Market, with forecasts for Product, Route of Administration, and Point of Sale, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 20 key national markets - See forecasts for the Asthma & COPD Therapies Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 18 of the major companies involved in the Asthma & COPD Therapies Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Asthma & COPD Therapies Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Asthma & COPD Therapies Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Introduction to the COPD and Asthma Therapies Market

  • 3.1 Introduction to the COPD and Asthma Therapies
  • 3.2 The Pharmaceutical Industry: A Very Brief Overview
  • 3.3 What is Asthma?
    • 3.3.1 Trends in Asthma Prevalence
    • 3.3.2 Pathophysiology of Asthma
    • 3.3.3 Symptoms of Asthma
    • 3.3.4 Causes and Triggers for Asthma
    • 3.3.5 Treatment of Asthma
    • 3.3.6 Drug Delivery Methods in Asthma
  • 3.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
    • 3.4.1 Trends in COPD Prevalence
    • 3.4.2 Pathophysiology of COPD
    • 3.4.3 Signs and Symptoms of COPD
    • 3.4.4 Treatment of COPD
    • 3.4.5 Drug Treatments for COPD
    • 3.4.6 Guidelines for COPD Treatment
  • 3.5 Major Drug Classes in the Treatment of Asthma and COPD
    • 3.5.1 Bronchodilators
      • 3.5.1.1 Beta2-Agonists
      • 3.5.1.2 Anticholinergics
    • 3.5.2 Anti-Inflammatory Drugs
      • 3.5.2.1 Corticosteroids
      • 3.5.2.2 Leukotriene Receptor Antagonists
      • 3.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
    • 3.5.3 Combination Drugs

4 Market Overview

  • 4.1 Key Findings
  • 4.2 Market Dynamics
    • 4.2.1 Market Driving Factors
    • 4.2.2 Increasing Prevalence of Respiratory Diseases on Account of Increasing Pollution
    • 4.2.3 Reducing Social Stigma Asthma and COPD
    • 4.2.4 Strong Pipeline for Asthma Drugs
  • 4.3 Market Restraints
  • 4.4 Market Opportunities
    • 4.4.1 Telehealth
  • 4.5 Porter's Five Forces
    • 4.5.1 Bargaining Power of Buyers
    • 4.5.2 Bargaining Power of Suppliers
    • 4.5.3 Threat of Substitutes
    • 4.5.4 Threat of New Entrants
    • 4.5.5 Industry Rivalry
  • 4.6 SWOT Analysis
  • 4.7 COVID-19 Impact Analysis

5 Asthma & COPD Therapies Market Analysis by Product

  • 5.1 Key Findings
  • 5.2 Product Segment: Market Attractiveness Index
  • 5.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Product
  • 5.4 Anti-inflammatory Drugs
    • 5.4.1 Anti-inflammatory Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)
  • 5.5 Bronchodilators Monotherapy
    • 5.5.1 Bronchodilators Monotherapy Submarket Forecast by Type, 2023-2033 (US$ bn)
  • 5.6 Combination Drugs
    • 5.6.1 Combination Drugs Submarket Forecast by Type, 2023-2033 (US$ bn)

6 Asthma & COPD Therapies Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Route of Administration
  • 6.4 Oral
    • 6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Inhaled
    • 6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Others
    • 6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Asthma & COPD Therapies Market Analysis by Point of Sale

  • 7.1 Key Findings
  • 7.2 Point of Sale Segment: Market Attractiveness Index
  • 7.3 Asthma & COPD Therapies Market Size Estimation and Forecast by Point of Sale
  • 7.4 Retail Pharmacies
    • 7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 7.4.2 Market Share by Region, 2023 & 2033 (%)
  • 7.5 Hospital Pharmacies
    • 7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 7.5.2 Market Share by Region, 2023 & 2033 (%)
  • 7.6 Others
    • 7.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
    • 7.6.2 Market Share by Region, 2023 & 2033 (%)

8 Asthma & COPD Therapies Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Asthma & COPD Therapies Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Asthma & COPD Therapies Market Attractiveness Index
  • 9.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 9.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 9.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 9.7 U.S. Asthma & COPD Therapies Market Analysis
  • 9.8 Canada Asthma & COPD Therapies Market Analysis

10 Europe Asthma & COPD Therapies Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Asthma & COPD Therapies Market Attractiveness Index
  • 10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 10.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 10.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 10.7 Germany Asthma & COPD Therapies Market Analysis
  • 10.8 UK Asthma & COPD Therapies Market Analysis
  • 10.9 France Asthma & COPD Therapies Market Analysis
  • 10.10 Italy Asthma & COPD Therapies Market Analysis
  • 10.11 Spain Asthma & COPD Therapies Market Analysis
  • 10.12 Rest of Europe Asthma & COPD Therapies Market Analysis

11 Asia Pacific Asthma & COPD Therapies Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Asthma & COPD Therapies Market Attractiveness Index
  • 11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 11.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 11.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 11.7 Japan Asthma & COPD Therapies Market Analysis
  • 11.8 China Asthma & COPD Therapies Market Analysis
  • 11.9 India Asthma & COPD Therapies Market Analysis
  • 11.10 Australia Asthma & COPD Therapies Market Analysis
  • 11.11 South Korea Asthma & COPD Therapies Market Analysis
  • 11.12 Rest of Asia Pacific Asthma & COPD Therapies Market Analysis

12 Latin America Asthma & COPD Therapies Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Asthma & COPD Therapies Market Attractiveness Index
  • 12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 12.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 12.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 12.7 Brazil Asthma & COPD Therapies Market Analysis
  • 12.8 Mexico Asthma & COPD Therapies Market Analysis
  • 12.9 Rest of Latin America Asthma & COPD Therapies Market Analysis

13 MEA Asthma & COPD Therapies Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Asthma & COPD Therapies Market Attractiveness Index
  • 13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
  • 13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
  • 13.5 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ bn)
  • 13.6 Market Size Estimation and Forecast by Point of Sale, 2023-2033 (US$ bn)
  • 13.7 GCC Asthma & COPD Therapies Market Analysis
  • 13.8 South Africa Asthma & COPD Therapies Market Analysis
  • 13.9 Rest of MEA Asthma & COPD Therapies Market Analysis

14 Company Profiles

  • 14.1 AstraZeneca
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Financial Analysis
      • 14.1.3.1 Net Revenue, 2015-2021
      • 14.1.3.2 Regional Market Shares, 2021
      • 14.1.3.3 Gross Profit, 2015-2021
      • 14.1.3.4 R&D, 2015-2021
    • 14.1.4 Product Benchmarking
    • 14.1.5 Strategic Outlook
  • 14.2 GSK plc
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
      • 14.2.3.1 Net Revenue, 2015-2021
      • 14.2.3.2 Regional Market Shares, 2021
      • 14.2.3.3 Gross Profit, 2015-2021
      • 14.2.3.4 R&D, 2015-2021
    • 14.2.4 Product Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 Boehringer Ingelheim
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2015-2021
      • 14.3.3.2 Regional Market Shares, 2021
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Teva Pharmaceutical Industries Ltd.
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2015-2021
      • 14.4.3.2 Regional Market Shares, 2021
      • 14.4.3.3 Gross Profit, 2015-2021
      • 14.4.3.4 R&D, 2015-2021
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Viatris Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2015-2021
      • 14.5.3.2 Gross Profit, 2015-2021
      • 14.5.3.3 R&D, 2015-2021
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 F. Hoffmann-La Roche Ltd.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2015-2021
      • 14.6.3.2 Gross Profit, 2015-2021
      • 14.6.3.3 R&D, 2015-2021
    • 14.6.4 Product Benchmarking
  • 14.7 Novartis AG
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2015-2021
      • 14.7.3.2 Regional Market Shares, 2021
      • 14.7.3.3 Gross Profit, 2015-2021
      • 14.7.3.4 R&D, 2015-2021
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Mundipharma
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
  • 14.9 Cipla Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2015-2021
      • 14.9.3.2 Regional Market Shares, 2021
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Pulmatrix
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Product Benchmarking
    • 14.10.4 Strategic Outlook
  • 14.11 TFF Pharmaceuticals, Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 Strategic Outlook
  • 14.12 Respiratorius AB
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Product Benchmarking
  • 14.13 Chiesi Farmaceutici S.p.A.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
  • 14.14 Grifols S.A.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2015-2021
      • 14.14.3.2 Regional Market Shares, 2021
      • 14.14.3.3 Gross Profit, 2015-2021
      • 14.14.3.4 R&D, 2015-2021
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Sanofi SA
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2015-2021
      • 14.15.3.2 Regional Market Shares, 2021
      • 14.15.3.3 Gross Profit, 2015-2021
      • 14.15.3.4 R&D, 2015-2021
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Sunovion Pharmaceuticals Inc.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Product Benchmarking
  • 14.17 Transpire Bio
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Product Benchmarking
  • 14.18 Verona Pharma plc
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Product Benchmarking
    • 14.18.4 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from
  • 15.2 Recommendations for Market Players